Smoking Intensity and Bladder Cancer Aggressiveness at Diagnosis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Mar 24

PMID 29570711

Citations 20

Authors

Andre L A Barbosa

Sita H H M Vermeulen

Katja K Aben

Anne J Grotenhuis

Alina Vrieling

Lambertus A Kiemeney

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the relation between cigarette smoking intensity and bladder cancer aggressiveness at first diagnosis.

Methods: Patients diagnosed with urinary bladder cancer (BC) between 1995-2011 under the age of 75 years were retrospectively identified from the Netherlands Cancer Registry and invited for a study on genetic and lifestyle risk factors for BC. Information on patients' self-reported smoking history was retrieved by means of a postal questionnaire. Tumors were stratified regarding the risk of progression defined by tumor stage and grade. Multinomial logistic regression was used to analyze the relation between smoking intensity and aggressiveness of the tumor.

Results: The UBC study population comprised 323 (17.4%) never smokers, 870 (46.8%) former cigarette smokers, and 630 (33.9%) current cigarette smokers. A higher smoking amount was a risk factor of getting high-risk non-muscle invasive bladder cancer (NMIBC) compared with low-risk NMIBC in ever and former cigarette smokers (OR: 1.02 per cigarette smoked, 95% CI: 1.00-1.03 and OR: 1.03, 95% CI: 1.01-1.05, respectively). A statistically significant dose-response increase in the risk of a more aggressive cancer type (high-risk NMIBC and MIBC) was observed with increasing smoking duration among former smokers (p for trend 0.035 and 0.008, respectively). No significant association of the evaluated smoking intensity variables was observed in current smokers. A longer time of smoking cessation correlated with a lower odds of a more aggressive cancer.

Conclusion: We observed a weak increase in the risk of a more aggressive tumor type with increasing smoking intensity in former smokers, but this association was absent in current smokers. This conflicting result may suggest that there is no strong relation between smoking intensity and bladder cancer aggressiveness. Analyses of prospective studies with longitudinal smoking assessment may provide a more definitive answer to the research question.

Citing Articles

Deep learning identifies histopathologic changes in bladder cancers associated with smoke exposure status.

Eminaga O, Lau H, Shkolyar E, Wardelmann E, Abbas M PLoS One. 2024; 19(7):e0305135.

PMID: 39083547 PMC: 11290674. DOI: 10.1371/journal.pone.0305135.

Smoking characteristics and years since quitting smoking of US adults diagnosed with lung and bladder cancer: A national health and nutrition examination survey analysis.

Beatrici E, Labban M, Filipas D, Stone B, Reis L, Dagnino F Int Braz J Urol. 2024; 50(2):199-208.

PMID: 38386790 PMC: 10953605. DOI: 10.1590/S1677-5538.IBJU.2023.0625.

Cytoplasmic Androgen Receptor, CD24 Expression and Smoking Intensity to Urothelial Carcinoma of the Bladder Invasiveness: A Cross-Sectional Study.

Pramod S, Safriadi F, Hernowo B, Dwiyana R, Trianasari N, Egawa S Res Rep Urol. 2023; 15:485-494.

PMID: 37933300 PMC: 10625756. DOI: 10.2147/RRU.S433705.

The Impact of En-bloc Transurethral Resection of Bladder Tumour on Clinical, Pathological and Oncological Outcomes: A Cohort Study.

Kannan D, Sekaran P, Sankaran S, Taur P, J S, Paul R Cureus. 2023; 15(7):e42523.

PMID: 37637640 PMC: 10457497. DOI: 10.7759/cureus.42523.

Impact of smoking on urologic cancers: a snapshot of current evidence.

Kumar R, Matulewicz R, Mari A, Moschini M, Ghodoussipour S, Pradere B World J Urol. 2023; 41(6):1473-1479.

PMID: 37093319 PMC: 10241723. DOI: 10.1007/s00345-023-04406-y.

References

Larue H, Allard P, Simoneau M, Normand C, Pfister C, Moore L . P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers. Carcinogenesis. 1999; 21(1):101-6. DOI: 10.1093/carcin/21.1.101. View

Rink M, Zabor E, Furberg H, Xylinas E, Ehdaie B, Novara G . Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. Eur Urol. 2012; 64(3):456-64. DOI: 10.1016/j.eururo.2012.11.039. View

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Grotenhuis A, Ebben C, Aben K, Witjes J, Vrieling A, Vermeulen S . The effect of smoking and timing of smoking cessation on clinical outcome in non-muscle-invasive bladder cancer. Urol Oncol. 2014; 33(2):65.e9-17. DOI: 10.1016/j.urolonc.2014.06.002. View

Jiang X, Castelao J, Yuan J, Stern M, Conti D, Cortessis V . Cigarette smoking and subtypes of bladder cancer. Int J Cancer. 2011; 130(4):896-901. PMC: 3210924. DOI: 10.1002/ijc.26068. View

Chang W, Chang Y, Pan C . Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection. Am J Surg Pathol. 2012; 36(3):454-61. DOI: 10.1097/PAS.0b013e31823dafd3. View

Kiemeney L, Thorlacius S, Sulem P, Geller F, Aben K, Stacey S . Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet. 2008; 40(11):1307-12. PMC: 4539560. DOI: 10.1038/ng.229. View

Ros M, Bueno-de-Mesquita H, Kampman E, Buchner F, Aben K, Egevad L . Fruit and vegetable consumption and risk of aggressive and non-aggressive urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition. Eur J Cancer. 2012; 48(17):3267-77. DOI: 10.1016/j.ejca.2012.05.026. View

Wallerand H, Bakkar A, Gil Diez de Medina S, Pairon J, Yang Y, Vordos D . Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. Carcinogenesis. 2004; 26(1):177-84. DOI: 10.1093/carcin/bgh275. View

10.

Yavorski J, Blanck G . Smoking correlates with increased cytoskeletal protein-related coding region mutations in the lung and head and neck datasets of the cancer genome atlas. Physiol Rep. 2017; 4(24). PMC: 5210378. DOI: 10.14814/phy2.13045. View

11.

MORRISON A, Proppe K, Verhoek W, Aoki K, Leck I, Ohno Y . Histologic features of bladder cancer in Boston, USA, Manchester, UK, and Nagoya, Japan. Int J Cancer. 1982; 30(6):701-5. DOI: 10.1002/ijc.2910300605. View

12.

McCormack V, Agudo A, Dahm C, Overvad K, Olsen A, Tjonneland A . Cigar and pipe smoking and cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2010; 127(10):2402-11. DOI: 10.1002/ijc.25252. View

13.

Mohseni M, Zand S, Aghamir S . Effect of smoking on prognostic factors of transitional cell carcinoma of the bladder. Urol J. 2007; 1(4):250-2. View

14.

Stenzl A, Cowan N, De Santis M, Kuczyk M, Merseburger A, Ribal M . Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011; 59(6):1009-18. DOI: 10.1016/j.eururo.2011.03.023. View

15.

Pfeifer G, Denissenko M, Olivier M, Tretyakova N, Hecht S, Hainaut P . Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002; 21(48):7435-51. DOI: 10.1038/sj.onc.1205803. View

16.

Babjuk M, Burger M, Zigeuner R, Shariat S, van Rhijn B, Comperat E . EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013; 64(4):639-53. DOI: 10.1016/j.eururo.2013.06.003. View

17.

Leppert J, Shvarts O, Kawaoka K, Lieberman R, Belldegrun A, Pantuck A . Prevention of bladder cancer: a review. Eur Urol. 2006; 49(2):226-34. DOI: 10.1016/j.eururo.2005.12.011. View

18.

Brooks D, Geller A, Chang J, Miller D . Occupation, smoking, and the risk of high-grade invasive bladder cancer in Missouri. Am J Ind Med. 1992; 21(5):699-713. DOI: 10.1002/ajim.4700210510. View

19.

Persad R, Fleming C, Chern H, Lesnick T, Collins C, Smith P . Environmental procarcinogen hypothesis of bladder cancer in humans: Dapsone hydroxylation as a susceptibility risk factor for aggressive bladder cancer. Urol Oncol. 2011; 3(1):18-26. DOI: 10.1016/s1078-1439(97)00019-7. View

20.

. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014; 507(7492):315-22. PMC: 3962515. DOI: 10.1038/nature12965. View